NASDAQ Framework: Summit Therapeutics Inc.

Biopharmaceutical company focused on innovative therapies 1.

Summit Therapeutics Inc., a biopharmaceutical company headquartered in Miami, Florida, focuses on the discovery, development, and commercialization of therapies that are patient, physician, caregiver, and societal friendly. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with anti-angiogenesis properties. Additionally, Summit's anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for treating multidrug-resistant infections. Summit has a collaboration and license agreement with Akeso Inc. to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan 2 3.

2: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. View Source3: Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world including China. View Source

UNKNOWN

The provided facts do not contain information about whether Summit Therapeutics Inc. is still led by its founders or if the founders are heavily involved.

MEDIUM RISK

Summit Therapeutics Inc. has shown both promising developments and some financial challenges. On the positive side, the company has raised $200 million from an unsolicited offer to purchase shares, which indicates strong investor interest and provides significant capital 4. Additionally, the company's lead candidate, Ivonescimab, has shown promising results in clinical trials, outperforming Merck's Keytruda in certain settings 5. However, the company reported a loss of $0.06 per share in Q1 2024, which aligns with expectations but still indicates ongoing financial losses 6. Given these mixed signals, Summit Therapeutics Inc. is assessed as MEDIUM RISK.

4: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source5: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source6: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source

NO

There is no evidence in the provided facts indicating that Summit Therapeutics Inc. is launching any new product offerings. The information mainly focuses on their existing development candidate, Ivonescimab, and financial activities.

Summit Therapeutics Inc. is strategically expanding its product roadmap through 2024 to 2026 by focusing on the development and commercialization of its lead candidate, Ivonescimab, a bispecific antibody for immunotherapy. The company has secured a significant collaboration and license agreement with Akeso Inc. to develop and commercialize Ivonescimab in key markets including the United States, Canada, Europe, and Japan 7 8. Additionally, Summit has raised $200 million to bolster its financial position and support its clinical advancements 9. The company is also enhancing its leadership team with key appointments, such as Jeff Huber to its Board of Directors, to drive its strategic initiatives forward 10.

7: (Menlo Park, California, US, and Grand Cayman, Cayman Islands, December 06, 2022) – Akeso Inc. (HKEX Code: 9926.HK, “Akeso”, or the “Company”), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced a collaboration and license agreement (the “Agreement”) with Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Summit”), to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the United States, Canada, Europe, and Japan (the “License Territories”). In addition, the Company will co-brand the product in the License Territories. View Source8: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. View Source9: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source10: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source

Sources

1: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. View Source2: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. View Source3: Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world including China. View Source4: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source5: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source6: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source7: (Menlo Park, California, US, and Grand Cayman, Cayman Islands, December 06, 2022) – Akeso Inc. (HKEX Code: 9926.HK, “Akeso”, or the “Company”), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced a collaboration and license agreement (the “Agreement”) with Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Summit”), to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the United States, Canada, Europe, and Japan (the “License Territories”). In addition, the Company will co-brand the product in the License Territories. View Source8: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. View Source9: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source10: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. Business Wire • 18 days ago SMMT -9.90% Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. Business Wire • 24 days ago SMMT -9.90% 7 Top Stocks Under $10: June 2024 Edition While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. Stocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. While cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a InvestorPlace • 27 days ago ACB SMMT -9.90% REBN 3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street These high-flying stocks could have more room to run if analysts are right. Motley Fool • last month VKTX SMCI SMMT -9.90% Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer. Zacks • last month SMMT -9.90% ARQT Summit Raises $200 Million; Also Expands License Territories for Ivonescimab MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million. Business Wire • last month SMMT -9.90% Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate Business Wire • last month SMMT -9.90% Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Business Wire • last month SMMT -9.90% Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre Benzinga • last month SMMT -9.90% MRK Summit reports data from Phase III NSCLC treatment trial In China, ivonescimab is approved in combination with chemotherapy based on the results of the HARMONi-A trial. Clinical Trials Arena • last month SMMT -9.90% Competitor to Merck's Keytruda Worries Some Investors Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Barrons.com • last month SMMT -9.90% Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, do Business Wire • last month SMMT -9.90% Why Summit Therapeutics Stock Is Sinking Today Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. Motley Fool • last month SMMT -9.90% Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced PREMIUM MT Newswires • last month SMMT -9.90% Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […] Insider Monkey • 2 months ago AKESF SMMT -9.90% Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements. GuruFocus.com • 2 months ago SMMT -9.90% Q1 2024 Summit Therapeutics Inc Earnings Call Q1 2024 Summit Therapeutics Inc Earnings Call Thomson Reuters StreetEvents • 2 months ago SMMT -9.90% IMAB Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Business Wire • 2 months ago SMMT -9.90% Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors MIAMI, April 11, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. Business Wire • 3 months ago SMMT -9.90% View Source